JPWO2020111167A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020111167A5 JPWO2020111167A5 JP2020557810A JP2020557810A JPWO2020111167A5 JP WO2020111167 A5 JPWO2020111167 A5 JP WO2020111167A5 JP 2020557810 A JP2020557810 A JP 2020557810A JP 2020557810 A JP2020557810 A JP 2020557810A JP WO2020111167 A5 JPWO2020111167 A5 JP WO2020111167A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- peptide
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 156
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 94
- 101001129654 Homo sapiens Prohibitin-2 Proteins 0.000 claims description 88
- 102100031156 Prohibitin-2 Human genes 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 66
- 150000001413 amino acids Chemical group 0.000 claims description 42
- 125000004122 cyclic group Chemical group 0.000 claims description 30
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 101710100909 Brefeldin A-inhibited guanine nucleotide-exchange protein 3 Proteins 0.000 claims description 19
- 102100028622 Brefeldin A-inhibited guanine nucleotide-exchange protein 3 Human genes 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 230000035755 proliferation Effects 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 230000026731 phosphorylation Effects 0.000 claims description 8
- 238000006366 phosphorylation reaction Methods 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 102000015694 estrogen receptors Human genes 0.000 claims description 6
- 108010038795 estrogen receptors Proteins 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 description 28
- 239000000262 estrogen Substances 0.000 description 28
- 238000000134 MTT assay Methods 0.000 description 19
- 231100000002 MTT assay Toxicity 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 230000001419 dependent effect Effects 0.000 description 11
- 239000002502 liposome Substances 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 9
- 230000000799 fusogenic effect Effects 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 108010069514 Cyclic Peptides Proteins 0.000 description 3
- 102000001189 Cyclic Peptides Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 Fmoc amino acid Chemical class 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000012405 in silico analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101100243778 Homo sapiens PHB2 gene Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001295 alanines Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002333 glycines Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 101150090473 phb-2 gene Proteins 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024005446A JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018225660 | 2018-11-30 | ||
| JP2018225660 | 2018-11-30 | ||
| PCT/JP2019/046505 WO2020111167A1 (ja) | 2018-11-30 | 2019-11-28 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005446A Division JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020111167A1 JPWO2020111167A1 (ja) | 2021-10-28 |
| JPWO2020111167A5 true JPWO2020111167A5 (cg-RX-API-DMAC7.html) | 2022-11-21 |
| JP7525855B2 JP7525855B2 (ja) | 2024-07-31 |
Family
ID=70853835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557810A Active JP7525855B2 (ja) | 2018-11-30 | 2019-11-28 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
| JP2024005446A Active JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005446A Active JP7726464B2 (ja) | 2018-11-30 | 2024-01-17 | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US12595289B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3889264A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7525855B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020111167A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516611D0 (en) | 1985-07-01 | 1985-08-07 | Du Pont Canada | Fire-retardant sheet material |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB9201180D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| AU7335396A (en) | 1995-11-01 | 1997-05-22 | Dnavec Research Inc. | Membrane-fusible liposome with the use of recombinant sendai virus |
| JP2000516090A (ja) | 1996-07-26 | 2000-12-05 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | 遺伝子的免疫化のための方法と試薬 |
| AU749544B2 (en) | 1998-06-25 | 2002-06-27 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen peptides originating in cyclophilin B |
| US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| JP5339291B2 (ja) | 2006-08-10 | 2013-11-13 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
| DK2738255T3 (en) | 2011-07-29 | 2017-03-06 | Univ Tokushima | ERAP1-Derived Peptide and its Use |
| JP6923135B2 (ja) | 2016-01-19 | 2021-08-18 | 国立大学法人徳島大学 | がん治療用ペプチド及びそれを含む医薬組成物 |
| CN111148752B (zh) | 2017-07-19 | 2024-01-16 | 国立大学法人德岛大学 | 肽衍生物和包含其的药物组合物 |
-
2019
- 2019-11-28 JP JP2020557810A patent/JP7525855B2/ja active Active
- 2019-11-28 EP EP19890179.5A patent/EP3889264A4/en active Pending
- 2019-11-28 US US17/297,986 patent/US12595289B2/en active Active
- 2019-11-28 WO PCT/JP2019/046505 patent/WO2020111167A1/ja not_active Ceased
-
2024
- 2024-01-17 JP JP2024005446A patent/JP7726464B2/ja active Active
-
2026
- 2026-02-23 US US19/546,921 patent/US20260209292A1/en active Pending
- 2026-02-23 US US19/546,792 patent/US20260234205A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110511280B (zh) | 一种透皮重组纤连蛋白及其应用 | |
| AU727662B2 (en) | Peptides having antiproliferative properties | |
| JP2023514611A5 (cg-RX-API-DMAC7.html) | ||
| HK1208040A1 (en) | Cell penetrating peptides to target eif4e | |
| CN114053427B (zh) | 一种多肽靶向药物及其制备方法和应用 | |
| JP2015522264A (ja) | 細胞透過性ペプチドおよび細胞透過性ペプチドを同定する方法 | |
| Chang et al. | Expression in Escherichia coli of open reading frame gene segments of HTLV-III | |
| JP2980334B2 (ja) | ラットの顎下腺から導出したペプチド及びポリペプチド、対応するポリクローナル及びモノクローナル抗体、対応するハイブリドーマ並びに診断、検出及び治療目的でのこれらの生成物の使用 | |
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| CN100577686C (zh) | 寡聚肽及其治疗hiv感染的用途 | |
| RU98112759A (ru) | Человеческий семафорин l (h-sema-l) и соответствующие семафорины в других видах | |
| US20190100557A1 (en) | Protransduzin b, a gene transfer enhancer | |
| Wojciechowska et al. | Synthesis and hybridization studies of a new CPP-PNA conjugate as a potential therapeutic agent in atherosclerosis treatment | |
| Cross et al. | Influence of α-helicity, amphipathicity and D-amino acid incorporation on the peptide-induced mast cell activation | |
| CN118772232B (zh) | 蛙皮素类多肽化合物及其用途 | |
| US20220340629A1 (en) | Myosin Derived Peptides and Related Compounds with Anticoagulant Activities | |
| Imhof et al. | Synthesis of linear and cyclic phosphopeptides as ligands for the N‐terminal SH2‐domain of protein tyrosine phosphatase SHP‐1 | |
| JPH06228002A (ja) | Pacapを含有するセクレトグラニンιι産生促進剤 | |
| CN112390874B (zh) | 一种合成多肽及其合成方法和应用 | |
| JP7726464B2 (ja) | Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬 | |
| JP2793216B2 (ja) | 粘膜による吸収を高める、ソルビン及び誘導ペプチド | |
| AU2017358552B2 (en) | Protransducine-C: gene transfer activator | |
| WO2025193770A1 (en) | Macrocyclic peptides | |
| CN112209991A (zh) | APC/Asef相互作用的三肽抑制剂及其应用 | |
| CN120818007A (zh) | Psd-95 pdz2拟肽类抑制剂及其应用 |